Dokumente im Korb
Helmholtz Zentrum München
|
Imprint
PuSH - Publication Server of Helmholtz Zentrum München
Navigation
Home
Deutsch
Research
Advanced Search
Browse by ...
... Journal
... Publication Type
... Research Data
... Publication Year
Publication overview
Support & Contact
Contact persons
Help
Data protection
Vogt, V.* ; Walcher, T.* ; Ansprenger, C.* ;
Braeu, M.
; Kroell, T.* ; Kraemer, D.M.* ; Köhne, C.H.* ; Hausmann, A.* ;
Buhmann, R.
;
Tischer, J.
;
Schmetzer, H.M.
Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
J. Immunother.
37
, 331-347 (2014)
DOI
Open Access Green
as soon as Postprint is submitted to ZB.
Abstract
Metrics
Extra information
Stem cell transplantations and donor lymphocyte infusions are promising immunotherapies to cure acute myeloid leukemia (AML). Leukemia-derived dendritic cells are known to improve antileukemic functionality of T cells. We evaluated the composition and development of distinct T-cell subtypes in AML patients (n=12) compared with healthy probands (n=5) before and during stimulation with leukemia-derived dendritic cells-containing DC (DC) or blast-containing mononuclear cells (MNC) in 0-7 days mixed lymphocyte cultures (MLC) by flow cytometry. AML patients' T-cell subgroups were correlated with antileukemic functionality before and after DC/MNC stimulation by functional fluorolysis assays. (1) Unstimulated T cells from AML patients presented with significantly lower proportions of activated, T+ cm, CD137+, and β-integrin T cells, and significantly higher proportions of T naive and Teff compared with healthy probands. (2) After 7 days of DC or MNC stimulation, T-cell profiles were characterized by (significantly) increased proportions of activated T cells with effector function and significantly decreased proportions of β-integrin+m T cells. (3) Antileukemic cytotoxicity was achieved in 40% of T cells after MNC stimulation compared with 64% after DC stimulation. Antileukemic activity after DC stimulation but not after MNC stimulation correlated with higher proportions of Tcm and Tnaive before stimulation, as well as with significantly higher proportions of activated and β-integrin+T cells. Furthermore, cutoff values for defined T-cell activation/differentiation markers and β-integrin+T cells could be defined, allowing a prediction of antileukemic reactivity. We could demonstrate the potential of the composition of unstimulated/DC-stimulated T cells for the lysis of AML blasts. Especially, AML patients with high numbers of Tnaive and T cm could benefit from DC stimulation; proportions of activated and β-integrin+ T cells correlated with increased antileukemic functionality and could serve to predict T cells' reactivity during stimulation. Refined analyses in the context of responses to immunotherapies are required. Copyright © 2014 by Lippincott Williams & Wilkins.
Altmetric
Additional Metrics?
[➜Log in]
Tags
Annotations
Special Publikation
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Corresponding Author
Keywords
Aml ; Dendritic Cells ; T-cell Differentiation ; T-cell Memory ; T-effector Cells ; β-integrins; Acute Myeloid-leukemia; Central Memory; In-vivo; Risk-factors; Effector; Transplantation; Lymphocytes; Generation; Expression; Subsets
Keywords plus
ISSN (print) / ISBN
1524-9557
e-ISSN
1537-4513
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Journal
Journal of Immunotherapy
Quellenangaben
Volume: 37,
Issue: 6,
Pages: 331-347
Article Number: ,
Supplement: ,
Series
Publisher
Lippincott Williams & Wilkins
Publishing Place
University
University place
Faculty
Publication date
0000-00-00
Application number
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Molecular Immunology (IMI)
CCG Hematopoetic Cell Transplants (IMI-KHZ)
Grants